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Summary 
Metformin has shown beneficial effects in a murine model of tuberculosis. Using in-vitro 
and in-vivo studies we show that metformin has beneficial effects on cellular metabolism, 
immune function and gene-transcription involved in innate host responses to M. 
tuberculosis in humans.  
 
  
 1 
Abstract  1 
Background 2 
Metformin, the most widely administered diabetes drug, has been proposed as a 3 
candidate adjunctive host-directed therapy for tuberculosis, but little is known about its 4 
effects on human host responses to Mycobacterium tuberculosis.  5 
Methods 6 
We investigated in-vitro and in-vivo effects of metformin in humans.  7 
Results 8 
Metformin added to peripheral blood mononuclear cells from healthy volunteers 9 
enhanced in-vitro cellular metabolism whilst inhibiting the mammalian target of rapamycin 10 
(mTOR) targets p70S6K and 4EBP1, with decreased cytokine production and cellular 11 
proliferation, and increased phagocytosis. Metformin administered to healthy human 12 
volunteers led to significant down-regulation of genes involved in oxidative 13 
phosphorylation, mTOR signaling and type I interferon response pathways, particularly 14 
following stimulation with M. tuberculosis, and upregulation of genes involved in 15 
phagocytosis and reactive oxygen species (ROS) production was increased. These in 16 
vivo effects were accompanied by a metformin-induced shift in myeloid cells from 17 
classical to non-classical monocytes. At a functional level, metformin lowered ex vivo 18 
production of TNF-α, IFN-𝛾 and IL-1β but increased phagocytosis and ROS production. 19 
Conclusion 20 
Metformin has a range of potentially beneficial effects on cellular metabolism, immune 21 
function and gene-transcription involved in innate host responses to M. tuberculosis. 22 
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 3 
Introduction 25 
Diabetes increases susceptibility to tuberculosis [1] and worsens tuberculosis outcome 26 
[2]. The mechanisms behind this increase in susceptibility are unclear and a role for 27 
diabetes drugs could be envisioned. In particular, the diabetes drug metformin is anti-28 
inflammatory and inhibits pathways such as mammalian target of rapamycin (mTOR) 29 
signalling, which are important in the host defence to M. tuberculosis [3]. Nonetheless 30 
metformin has been demonstrated to enhance mycobacterial clearance in mice [4] and is 31 
associated with lower rates of M. tuberculosis infection in humans [5]. Adding to that, the 32 
use of metformin in humans has been associated with a plethora of positive effects, 33 
potentially linked to glycaemic control, such as a reduced risk of developing active TB [6, 34 
7], lower TB mortality [8], increased TB treatment success, reduced TB-relapse [9] and 35 
enhanced culture conversion [9, 10].  36 
Proposed mechanisms for metformin’s beneficial effects include an increase in 37 
mitochondrial reactive oxygen species (mROS) and enhanced killing of M. tuberculosis 38 
but none of these have been investigated in humans. Importantly the mechanism of action 39 
behind metformin’s effects are not clearly defined as metformin acts through several 40 
pathways including mitochondrial complex I inhibition, an increase in AMP/ATP levels 41 
leading to increased AMP activated kinase (AMPK) signaling, and decreased glucagon 42 
and mTOR signaling [11]. Lastly it is challenging to study the effects of metformin in 43 
people living with diabetes as characteristics of diabetes such as hyperglycaemia, 44 
dyslipidaemia, vitamin D deficiency and oxidative stress may all affect immune responses 45 
to M. tuberculosis [12].  46 
 4 
We therefore investigated the effects of metformin in humans without diabetes. We first 47 
characterised metformin's effects on in-vitro responses to M. tuberculosis and then 48 
validated these findings in vivo in healthy volunteers, showing that metformin alters 49 
mTOR signaling, inhibits p38 and AKT, rewires blood cellular landscape and enhances 50 
anti-M. tuberculosis responses.   51 
 5 
Methods 52 
Healthy Volunteers and Functional laboratory assays 53 
In the in vivo study 11 healthy Dutch adults were given metformin in increasing doses 54 
ending with a commonly used dose of 1000 mg twice a day. For all other in vitro 55 
experiments blood from healthy Dutch adults (estimated tuberculosis incidence 56 
1.5/100,000) was subject to analysis in the presence or absence of metformin. Isolated 57 
PBMCs, CD14+ monocytes or M1 / M2 macrophages were stimulated with M. tuberculosis 58 
lysate for production of tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, IL-59 
17A, IL-22 and interferon gamma (IFN-γ). Proliferation of CD4+ cells was measured by 60 
flow cytometry of Carboxyfluorescein succinimidyl ester (CFSE) labelled PBMCs 61 
stimulated for 6 d with M. tuberculosis lysate. Metabolic measurements included lactate 62 
production in stored cell culture supernatants, the NAD+/NADH redox ratio in cell lysates, 63 
glucose consumption and mitochondrial mass and potential. Activation of downstream 64 
mTOR targets signalling was assessed by western blot of phosphorylated(p)-AMPK, p-65 
p70 S6K, p-4EBP1, p-P38 and p-AKT . Production of Reactive Oxygen Species (ROS) 66 
was determined after incubation of whole blood or PBMCs with zymosan or M. 67 
tuberculosis lysate by measurement of chemiluminescence after the addition of luminol. 68 
Phagocytosis was measured in PBMCs using pHrodo® Green Zymosan Bioparticles® 69 
Conjugate and flow cytometry. M. tuberculosis infection was measured in PBMCs 70 
incubated with M. tuberculosis (H37Rv) at a multiplicity of infection (MOI) of 5 for 3 hours, 71 
lysed, and cultured on Middlebrook 7H11. Cellular viability of PBMCs was assessed by 72 
flow cytometry of Annexin V-FITC and propidium-iodide stained PBMCs.  73 
 74 
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Transcriptomics  75 
RNA-Seq (GSE102678) analysis was performed on participants’ samples pre- and post- 76 
metformin administration, directly on ex vivo whole blood and on isolated PBMC following 77 
incubation with M. tuberculosis lysate. Libraries were prepared using stranded 78 
preparation reagents from Illumina and sequenced on a NextSeq500, generating ~36-79 
45M million 43bp paired-end reads per sample. Sequence files were aligned to the human 80 
genome and aligned reads were counted. Differentially expressed genes were 81 
determined using the R package DESeq2, and gene set analyses were performed to 82 
determine how metformin affected biological pathways in vivo and in the in vitro response 83 
to M. tuberculosis.  qRT-PCR was performed to validate RNA-Seq and functional assay 84 
results. 85 
 86 
CyTOF marker labelling, data acquisition and analysis  87 
PMA and ionomycin stimulated PBMCs were stained with heavy-metal isotope-labeled 88 
antibodies (Table E1) [13], barcoded and were acquired on CyTOF 1 (Fluidigm). Samples 89 
were de-barcoded using manual gating in FlowJo and analysis of live CD14+/-CD16+/- 90 
monocytes was carried out using the t-distributed stochastic neighbor embedding (tSNE) 91 
dimension reduction and Phenograph-based clustering algorithm [14]. See 92 
Supplementary Methods for details on Mass Cytometry and statistical analysis. 93 
 94 
Statistics 95 
 7 
All values are expressed as the mean ± SEM of individual samples. Unless otherwise 96 
specified data analysis was performed using GraphPad Prism Software (GraphPad 97 
Software Inc.) using paired t-test or Wilcoxon signed-rank test. 98 
 99 
Study Approval 100 
Written informed consent was received from participants prior to inclusion in the study. 101 
Experiments were conducted according to the principles expressed in the Declaration of 102 
Helsinki. Both for the in vitro (NL32357.091.10) and healthy volunteers (NL47793.091.14) 103 
studies ethical approval was granted by the Arnhem-Nijmegen Ethical Committee. As 104 
validation EDTA blood from 10 healthy young subjects given metformin (500 mg day 1-105 
2) increasing to 1000 mg (day 3-8) was examined as part of a pharmacokinetic study 106 
(NL53534.091.15). The human RNA Seq study was approved by the LSHTM Research 107 
Ethics Committee (#11968). 108 
  109 
 8 
Results 110 
Metformin regulates cellular metabolism and cytokine production in humans 111 
We assessed the effects of metformin on glycolytic metabolism in human cells. When 112 
added to M. tuberculosis lysate-stimulated PBMCs from healthy individuals metformin 113 
increased lactate production and glucose consumption (Fig. 1A and 1B) whilst decreasing 114 
the NAD+/NADH ratio (Fig. 1C).  At both therapeutic (10 – 220 µM) and experimental 115 
concentrations [15] metformin showed clear effects on cytokine production. Depending 116 
on cell type different concentrations of metformin significantly decreased M. tuberculosis 117 
lysate-induced (i) TNF-α, IL-10, IFN-𝛾 and IL-17 production from PBMCs (Fig. 2A), (ii) IL-118 
1β, IL-6 and IL-10 from M1 and M2 monocyte derived macrophages (Fig. 2B) and (iii) 119 
TNF-α, IL-1 β and IL-10 from CD14+ monocytes (Supplemental Fig. S1A). At a 120 
transcriptional level metformin inhibited expression of IL-18, IL-23p19 and TGF-β1 genes 121 
(Fig. 2C). The minimal effect of metformin on cellular proliferation (Fig. 2D) is unlikely to 122 
account for the strong effects on cytokine production (Fig. 2E). Finally, although only 123 
suggestive, metformin also decreased the phosphorylation levels of the downstream 124 
mTOR targets, phospho-p70S6K and phospho-4EBP1, whilst increasing phosphorylation 125 
of its known molecular target, AMPK (Supplemental Fig. S1B). Metformin at the doses 126 
tested also had no significant effect on cellular viability (Supplemental Fig. S1C).  127 
 128 
Transcriptional profiling reveals a metformin-related gene expression signatures in 129 
humans  130 
Next, we investigated the in vivo effect of metformin. Healthy subjects took standard dose 131 
metformin and blood was drawn at several time-points before and after metformin intake 132 
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(Fig. 3A). As expected phospho-AMPK was increased in both unstimulated and M. 133 
tuberculosis lysate stimulated PBMCs after metformin intake (Td6 vs Td0) (Fig. 3B – 3D 134 
and Supplemental Fig. S2A). In genome-wide (unbiased) transcriptional analysis using 135 
RNA sequencing (RNAseq) on whole blood, metformin intake had no significant effects 136 
on individual genes (Supplemental Fig. S2B). Instead, a consistent metformin-mediated 137 
effect was observed on combined sets of genes (Fig. 3E), including a significant 138 
downregulation of OXPHOS and ribosome pathways and a significant upregulation of 139 
endocytosis/phagocytosis, MAPK and chemokine signaling pathways. 140 
In PBMCs, metformin intake led to differential expression of approximately 800 genes, 141 
both in unstimulated and M. tuberculosis lysate stimulated cells (Supplemental Fig. S2C). 142 
In unstimulated PBMCs, metformin intake led to upregulation of genes involved in mitosis, 143 
and downregulation of genes involved in OXPHOS, adipogenesis and myc targets (Fig. 144 
3F). In M. tuberculosis stimulated PBMCs, metformin intake led to suppression of genes 145 
involved in (i) signaling of cytokines such as IFN-α, IFN- and TNF-α, (ii) OXPHOS and 146 
(iii) mTOR (Fig. 3F) all in line with the in vitro effects of metformin (Fig. 1 and Fig. 2 147 
respectively). 148 
 149 
Cytokine responses to M. tuberculosis are suppressed by metformin in vivo 150 
Each gene ontology (GO) group in the identified gene sets was investigated and the 151 
“response to type 1 interferon” GO set showed the most markedly reduced expression in 152 
ex vivo M. tuberculosis lysate-stimulated PBMCs from individuals taking metformin 153 
(Supplemental Fig. S2D). Within this GO, the expression of eight genes (Interferon-154 
induced protein with tetratricopeptide repeats (IFIT) 1, IFIT 2 and IFIT 3, 2'-5'-155 
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oligoadenylate synthase (OAS) 1, OAS2 and OAS3, MX dynamin like GTPase (MX) 1 156 
and radical S-adenosyl methionine domain containing 2 (RSAD2) was more than two-fold 157 
reduced following metformin administration in cells stimulated with M. tuberculosis lysate 158 
for 4 hours (Fig. 4A), and to a lesser extent at 24 hours, as shown by qRT-PCR (Fig. 4A). 159 
Additionally, metformin intake led to a significant decrease in TNF-α, IL-1β, IL-6, IFN-𝛾 160 
and IL-17 release in response to M. tuberculosis lysate (Fig. 4B), with effects on cytokine 161 
production up to 21 d post metformin intake. Collectively, our results indicate that 162 
metformin inhibits M. tuberculosis-induced type 1 interferon response and inflammation 163 
in human PBMCs. 164 
 165 
Metformin regulates the AKT-mTOR pathway and mitochondrial metabolism in humans 166 
The MAPK, AKT and mTOR pathways are known to strongly influence cytokine 167 
production and so respectively the levels of phospho- and total-P38 (Fig. 4C and 168 
Supplemental Fig. S3A), phospho-AKT and phospho-4EBP1 (Fig. 4D and Supplemental 169 
Fig. S3B) were measured in PBMCs pre- and post-metformin intake. An overall decrease 170 
in the phosphorylation of all three targets were observed. Quantitative band intensity 171 
analysis showed that the ratio of p-P38 to total-P38, the levels of p-AKT/actin and p-172 
4EBP1/actin were in most cases significantly reduced due to metformin intake (Fig. 4E). 173 
Supplemental Figs. S3C-E demonstrate the effects on phosphorylation at an individual 174 
level. For further evidence we analysed the effect of metformin on the gene expression 175 
levels of these enzymes and found a decrease in expression of AKT2 (fitting with 176 
metformin’s role in homeostasis) and an increase in PRKAB2 (a regulatory subunit of 177 
AMPK) (Supplemental Fig. S3F). As AKT and mTOR are central metabolic regulators [16, 178 
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17] we investigated the effects of metformin on mitochondrial mass (Supplemental Fig. 179 
S4A). Metformin increased the mitochondrial mass of CD14+CD16- classical monocytes 180 
as demonstrated by increased Mitotracker green median fluorescence intensity (MFI; Fig. 181 
4F). This increase was not observed for CD14-CD16+ non-classical monocytes 182 
(Supplemental Fig. S4B). This highlights metformin mediated alterations in mitochondrial 183 
functionality in CD14+CD16- classical monocyte which may correlate with the anti-184 
inflammatory effect of metformin [18, 19].  185 
 186 
Metformin modulates the peripheral monocyte landscape in humans 187 
Metformin intake altered the number and distribution of circulating immune cells. In whole 188 
blood metformin led to a transient increase in total white blood cells (WBC) and 189 
neutrophils (Fig. 5A) without altering the relative distribution of cell types (Fig. 5B). In 190 
PBMCs metformin increased the proportion of monocytes and decreased the proportion 191 
of lymphocytes (Fig. 5C).  192 
 193 
To achieve a single cell systems-level perspective of the effect of metformin on 194 
monocytes, PBMCs from pre- (Td0) and post-metformin intake (Td6) blood, were 195 
stimulated with phorbol ester and ionomycin,  stained with a panel of 38 surface and 196 
intracellular cytokine markers (Table S1) and analysed using CyTOF [20]. We first verified 197 
the panel antibodies for their binding to the PBMCs (Supplemental Fig. S5) and then 198 
gated out the pure population of monocytes (CD3-CD19-CD56-γδTCR-Vd1-VD2-CD57-199 
CD161-CD14+/-CD16+/-) for analysis (Supplemental Fig. S6). Analysis of monocytes using 200 
tSNE in conjunction with a phenograph clustering algorithm [14, 21] identified 12 distinct 201 
 12 
cell clusters with shared surface and intracellular marker expression characteristics (Fig. 202 
5D and 5E). Based on the expression of CD14, CD16 and CCR2 the 12 clusters were 203 
divided into 5 monocyte subsets (Fig. 5E), illustrating significant heterogeneity among the 204 
classical and non-classical monocyte population in humans. Three out of 12 clusters were 205 
found to be significantly enriched or depleted in Td6 samples compared to Td0. These 206 
differentiated clusters included diverse activated phenotypes, i.e. CD14hiCD16-MIP-207 
1β+IL-2-TNFα- (Cluster 2, downregulated); CD14hiCD16-MIP-1β+IL-2+TNFα- (Cluster 10, 208 
downregulated) and CD14loCD16loMIP-1β+IL-2-TNFα+ (Cluster 5, upregulated) (Fig. 5F). 209 
The accuracy of machine-learning automated gating when validated by manual gating 210 
indeed showed that clusters 2 and 10 were CD14hiCD16- whereas cluster 5 was 211 
CD14loCD16mid (Supplemental Fig. S7A). Furthermore, when assessed for cytokine 212 
secretion by manual gating, only cluster 5 and 10 was found to express TNFα and IL-2 213 
respectively (Fig. 5F), similar to as identified by tSNE analysis; while all three clusters 214 
(cluster 5, 10 and 2) were found to express MIP-1β (Fig. 5F) confirming the tSNE analysis. 215 
The manual gating strategy also indicated a trend towards a decreased total population 216 
frequencies of CD14hiCD16- classical monocytes or increased CD14-CD16+ non-classical 217 
monocytes (Supplemental Fig. S7B). Collectively, our results delineate the effect of 218 
metformin on the functional capacity of heterogeneous peripheral monocytes.  219 
 220 
Metformin enhances innate host defense pathways in exposed human leukocytes 221 
Metformin intake showed clear effects on innate host defense mechanisms. ROS 222 
production was strongly upregulated in whole blood in samples immediately post 223 
metformin treatment (Td6), both spontaneously and upon stimulation with M. tuberculosis 224 
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lysate and zymosan (Fig. 6A). In line with increased ROS production in whole blood, 225 
genes involved in ROS production such as NADPH Oxidase 2 (CYBB), p22-PHOX 226 
(CYBA), RAC1 and particularly for ROS production in neutrophils p47-PHOX (NCF1), 227 
p67-PHOX (NCF2) and p40-PHOX (NCF4) were strongly upregulated in blood after 228 
metformin intake (Fig. 6B). The increase in ROS did not correlate with an increase in 229 
white blood cell counts or neutrophil counts (Supplemental Fig. S8B and S8C). No 230 
increase in ROS was observed in isolated PBMCs (Supplemental Fig. S8A).   231 
 232 
Whole blood RNAseq analysis revealed that metformin upregulated genes involved in 233 
endocytosis such as receptors (RTKs and GPCR), regulators of clathrin-mediated pit 234 
formation (AP2) and clathrin uncoating (Hsp70) and regulators of intracellular vesicular 235 
trafficking (Arfs, ArgGAPs and ArfGEFs) (Supplemental Fig. S9A). Increased 236 
phagocytosis following metformin intake was confirmed in a second group of healthy 237 
subjects taking metformin, using zymosan labelled beads in whole blood (Fig. 6C). The 238 
increase in phagocytosis correlated with an increase in WBC counts but not neutrophil 239 
counts (Supplemental Fig. S9B). Furthermore in vitro metformin pre-treated PBMCs also 240 
showed upregulated phagocytosis (Supplemental Fig. S9C). Finally, we examined the 241 
effect of metformin on the killing of M. tuberculosis. Out of eight subjects, metformin led 242 
to restricted ex vivo growth of M. tuberculosis in four subjects. Overall there were no 243 
significant differences (Fig. 6D). The CFU results were unaffected by normalization to 244 
monocyte numbers.  245 
  246 
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Discussion 247 
 248 
A study in mice and retrospective human data suggest that metformin, the most widely 249 
used diabetes drug, may improve outcome of tuberculosis [4, 6, 8]. We examined how 250 
metformin modulates the peripheral immune cell distribution, its gene expression and its 251 
functional output in humans using high dimensional phenotypic and RNA analyses. 252 
Metformin administration was found to dampen pro-inflammatory cytokine production 253 
whilst promoting phagocytosis and ROS production, possibly through the generation of 254 
non-classical monocytes, which are implicated in trained innate immunity [22]. These 255 
functional changes were associated with an inhibition of the type 1 interferon pathway, 256 
and a decrease in p-AKT and p-P38 signaling and an increase in AMPK signaling. Our 257 
data are in line with increasing evidence that metformin possesses anti-inflammatory 258 
properties, considered to be mediated in part via alterations in cellular metabolism [23]. 259 
A strong effect of metformin on inflammatory cytokine signalling was observed both in 260 
vitro and in vivo. Metformin inhibited the type I interferon response by blocking the 261 
expression of interferon-stimulated genes IFIT1, IFIT2 and IFIT3, which amongst other 262 
activities, regulate inflammatory cytokine mRNA stability, cell proliferation and apoptosis 263 
[24]. Neutrophil driven type 1 interferon signaling in blood, including upregulated IFIT1, 264 
IFIT2, IFIT3 and genes similar to those in our data [25], but not type 1 IFNs themselves,  265 
have been identified as a signature of active tuberculosis disease [26] and inhibiting this 266 
pathway using zileuton, an arachidonic acid metabolism modulator, protects mice from 267 
tuberculosis [27]. Our data show that metformin can down-regulate the type-1 interferon 268 
pathway in humans.  269 
 15 
ROS production and phagocytosis were increased by metformin and this was not 270 
explained by altered cell counts, suggesting that the observed effects are intrinsically 271 
mediated by metformin. This is supported by the accompanying transcriptional changes 272 
observed in both ROS and phagocytosis related genes and the increase in phagocytosis 273 
induced by metformin in vitro. Mechanistically, AMPK activation has been linked to 274 
phagocytosis activity as pharmacologic [28, 29] or genetic ablation [30, 31] of AMPK 275 
subunits negatively influenced phagocytosis. It will be interesting to investigate the effect 276 
of metformin on autophagy  in future studies and to determine how it compares with an 277 
elegant study showing that autophagic capacity does not correlate with M. tuberculosis 278 
susceptibility in mice [32]. As ours is the first exploratory study of the effects of metformin 279 
on host defense in vivo in non-diabetic individuals future studies should examine the 280 
effect of metformin on the phagocytic capacity of specific cell types such as macrophages 281 
and dendritic cells.   282 
 283 
Metformin intake increased ex vivo mycobacterial killing capacity of PBMCs in some 284 
individuals but not all. In earlier work, we found that mycobacterial survival decreased in 285 
metformin-treated human macrophages [4]. This effect of metformin was reversed by the 286 
inclusion of ROS-scavenging agents. It is possible that five days of metformin exposure 287 
in vivo is too short, that the effect of metformin on killing capacity of PBMCs is somewhat 288 
lost during cryopreservation, or that other cells such as neutrophils contribute to the anti-289 
mycobacterial effects of metformin. Future studies could use bronchiolar lavage cells to 290 
investigate control mechanisms from the disease site rather than in peripheral blood. 291 
Alternatively, metformin could have subtle effects on mycobacterial killing and bigger 292 
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effects on ameliorating inflammation. Whilst pro-inflammatory cytokines are required for 293 
the control of M. tuberculosis, it is the balance between pro and anti-inflammatory 294 
cytokines that is important for the restriction of mycobacterial growth and prevention of 295 
overt pathology   [33, 34]. Here, we found that metformin dampens the expression of pro-296 
inflammatory cytokines whilst simultaneously enhancing anti-mycobacterial processes 297 
such as phagocytosis and ROS.  298 
 299 
In mice, we have previously shown metformin-mediated restriction of M. tuberculosis 300 
outgrowth [4] although another study found no additive effect of metformin when 301 
combined to the standard tuberculosis treatment [35]. In diabetic tuberculosis patients, 302 
metformin use has been linked with more rapid culture conversion [9], particularly in 303 
patients with cavitary lung disease and high bacterial burden [10], and with better 304 
treatment outcomes [9], indicating that the net result of all the effects of metformin is 305 
enhanced mycobacterial control in vivo.  In a cohort of 296 diabetic tuberculosis patients 306 
in Singapore [4] metformin was associated with lower mortality and a similar association 307 
was found amongst a cohort of 634 diabetic patients in Taiwan [8]. However, neither of 308 
these two cohort studies included microbiological data. The survival difference could 309 
equally be explained by the well-known beneficial effects of metformin on cardiovascular 310 
mortality or its immuno-modulating effects as found in this study. Future clinical trials in 311 
non-diabetic tuberculosis patients will help establish the effect of metformin on clinical 312 
and microbiological outcome of tuberculosis treatment.   313 
 314 
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Metformin is put forward as a candidate for host-directed therapy in tuberculosis but some 315 
caution is warranted. For example, in a model of candidemia metformin resulted in 316 
increased lethality [36]. Also, it is unknown if tuberculosis or concurrent use of anti-317 
tuberculous drugs increase the risk of metformin-associated gastrointestinal side-effects 318 
or lactic acidosis [37]. With regard to possible drug interactions, a recent study in diabetic 319 
tuberculosis patients has shown that rifampicin increases metformin exposure, but does 320 
not alter blood glucose levels. 321 
 322 
In summary metformin effectively modulates the balance between inflammation and 323 
effective host responses to M. tuberculosis. It ameliorates the pathological inflammatory 324 
responses associated with tuberculosis whilst enhancing anti-mycobacterial processes 325 
such as ROS and phagocytosis in humans.  326 
  327 
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Figure Legends 465 
Fig. 1. Metformin alters mTOR signalling axis whilst maintaining glucose regulatory 466 
effects. (A) Lactate production, (C) glucose consumption and (D) NAD+/NADH fold 467 
change in PBMCs stimulated with M. tuberculosis lysate in the presence or absence of 468 
1000µM metformin for 24h, 48h, or 7d.  For A, data are from two individual experiments. 469 
For A-C data are shown as means ± S.E.M. from 2-3 experiments/6- 9 donors. * p<0.05, 470 
** p<0.01 (Wilcoxon matched-pairs signed rank test).  471 
 472 
Fig. 2. Metformin affects the cytokine profile of human cells stimulated with M. 473 
tuberculosis.  Cytokine production from (A) human PBMCs and (B) monocyte-derived 474 
M1 and M2 macrophages stimulated with M. tuberculosis lysate +/- 3–3000µM of 475 
metformin for 24h (TNF-α, IL-6, IL-1β and IL-10) or 7 d ( IFN-𝛾, IL-17 or IL-22), and (C) 476 
cytokine gene expression in CD14+ monocytes stimulated with M. tuberculosis lysate 477 
+/- 3000µM metformin after 4 h (IL-18 and TGF-β1) or 24 h (IL-23p19 and IL-12p35 478 
subunits). (D) Percentage CD4+ T cell proliferation in PBMCs stimulated with M. 479 
tuberculosis lysate in the presence or absence of 300 µM metformin for 6 d, using 480 
CFSE labelling to track generations. (E) Radial graph representing fold-change in 481 
cytokines from PBMCs stimulated with M. tuberculosis lysate in the +/- 3000µM 482 
metformin, relative to stimulation in absence of metformin. Values < 1 indicate reduced 483 
cytokine production. This is indicated by projection towards the centre of the radius. For 484 
A-C and E all data (mean ± s.e.m.) are from 3 experiments/6-13 donors. For D data are 485 
(mean ± s.e.m.) from four experiments/ 7 donors. * p<0.05, ** p<0.01 (Wilcoxon 486 
matched-pairs signed rank test for A-C and Paired t-test for D.  487 
 26 
Fig. 3. Global effects of metformin in healthy human volunteers.  (A) Healthy volunteers 488 
(n =11) received an increasing dose of metformin for five consecutive days. Blood was 489 
drawn twice pre-(TdB) and several times post-metformin treatment. (B) Western blot 490 
analysis of p-AMPK in lysates of PBMCs, collected from healthy volunteers before and 491 
after metformin intake and stimulated for 2h with RPMI(-) or M. tuberculosis lysate (+): 492 
four representative donors are shown.  (C) Quantitative relative band intensity analysis 493 
of p-AMPK between pre- (Td0) and post-metformin (Td6) periods for RPMI and M. 494 
tuberculosis lysate stimulation: data are mean ± S.E.M. from eight donors. (D) Fold 495 
change in p-AMPK levels between pre- (Td0) and post-metformin (Td6) periods for 496 
RPMI and M. tuberculosis lysate stimulation for eight donors.  * p<0.05, ** p<0.01 497 
(Paired t test). All western blot data depicted here are normalized to the loading control 498 
actin. (E) Gene set analysis from RNA-Seq data showing KEGG pathways which were 499 
differentially expressed in ex vivo blood samples following metformin administration. 500 
The bar length indicates the magnitude of the change of expression of the gene set.  501 
Data were analyzed using the Piano R package, and pathways with adjusted P<0.01 502 
are shown. (F) Hallmark gene set enrichment and network analysis, showing gene sets 503 
up- (red) or down- (blue) regulated following metformin administration in PBMCs in 504 
either resting state or stimulated with M. tuberculosis lysate for 4h. The colour intensity 505 
indicates the adjusted P-value for the gene set enrichment.  506 
 507 
Fig. 4. Metformin intake in healthy volunteers affects cytokine production via P38 and 508 
AKT inhibition. (A) Expression of eight genes in the “response to type 1 interferon” Gene 509 
Ontology group in PBMCs stimulated with M. tuberculosis lysate in vitro for 4 or 24 h, 510 
 27 
before and after in vivo metformin administration in healthy volunteers. Expression 511 
measured by RNA-Seq (4hr) and qRT-PCR (4 and 24hr). (B) Cytokine production from 512 
isolated PBMCs stimulated with M. tuberculosis lysate 24h (TNF-α, IL-6, IL-1β and IL-513 
10) or after 7d (IFN-𝛾, IL-17 or IL-22) in the presence of 10 % pooled human serum 514 
before and after metformin intake. (C) Western blot analysis of p-38 and Total p38 and 515 
(D) p-AKT and p-4EBP1 levels in lysates of PBMCs stimulated for 2h RPMI (-) or M. 516 
tuberculosis lysate (+) from healthy volunteers before and after metformin intake. Data 517 
are representative of four of eight measured donors from the trial. All western blot data 518 
depicted here are normalized to the loading control actin. (E) Fold change in p-38/Total 519 
p38 levels, p-AKT/actin or p-4EBP1/actin between pre- (Td0) and post-metformin (Td6) 520 
periods for RPMI and M. tuberculosis lysate stimulation. (F) Mitochondrial mass 521 
assessment in CD14+CD16- monocytes: left panel – overlay of before and after 522 
metformin from same individual, right panel - MFI of MitoTracker Green from n=3 523 
samples. Grey – FMO control. * p<0.05, ** p<0.01 (Paired t test). All western blot data 524 
(mean ± S.E.M.) are representative of a total of eight donors presented in (C) or (D) or 525 
Supplementary Fig. 3A or 3B.   526 
 527 
Fig. 5. Metformin intake in healthy volunteers alters the blood cellular composition 528 
landscape. Analysis of leukocyte counts plotted (A) as raw cell counts for whole blood, 529 
(B) as percentage of total counts for whole blood and (C) as percentage of total counts 530 
for isolated PBMCs. (D) Cryo-preserved PBMCs before (Td0) and after (Td6) metformin 531 
intake were stimulated with PMA-ionomycin and analysed by mass cytometry. tSNE 532 
analysis of single-cell data from blood monocytes of analyzed samples. Cells were 533 
 28 
plotted and color-coded by the 12 ‘unsupervised’ phenograph clusters. (E) Heat-plot 534 
summary of average  median expression of each marker analysed for the 12 clusters 535 
identified. 12 clusters are divided into five subsets based on the expression of CD14, 536 
CD16 and CCR2.  (F) Mass cytometry data was analyzed by manual gating strategy. 537 
The 3 differentially regulated monocyte clusters were overlayed to assess the 538 
expression of cytokines. Table on right indicates the depiction of (in terms of + and -) 539 
which cluster express which cytokine based on the manual gating strategy.  540 
 541 
Fig. 6. Metformin intake in healthy volunteers affects ex-vivo anti-mycobacterial defence 542 
mechanisms but not M. tuberculosis outgrowth. (A) ROS production as measured by 543 
luminol-reaction from whole blood from pre- and post-metformin treated volunteers 544 
unstimulated (RPMI) or stimulated with M. tuberculosis lysate (Mtb) or zymosan. Data 545 
are representative of 11 individual donors. Bars representing the fold-change of Td6, 546 
Td9 or Td21 over Td0 for each individual donor are superimposed with grey dots 547 
representing the mean ± s.e.m. (B) Expression of six genes encoding key NADPH 548 
oxidase proteins for ROS production were assessed in ex vivo blood by RNA-Seq 549 
before and after administration of metformin in the healthy volunteers. * p<0.05, ** 550 
p<0.01 (Wilcoxon matched-pairs signed rank test). (C) Net phagocytosis of pHrodo 551 
conjugates in healthy volunteers given metformin for seven days. Lysed blood was 552 
incubated with the pH rodo suspension for 2 h in a non-CO2 elevated incubator at 37°C 553 
before measuring fluorescence. (D) Colony forming units (CFU)/mL between 24 h or 48 554 
h and 3 h of infection of PBMCs from pre- and post-metformin treated volunteers 555 
infected with mycobacteria. Data was normalised to monocyte count.  556 
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